K. Groot

发表

Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes

A. Bajo, A. Schally, M. Krupa, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Effect of luteinizing hormone-releasing hormone analogs containing cytotoxic radicals on the function of rat pituitary cells: tests in a long term superfusion system.

A. Schally, K. Groot, Z. Rékási, 1993, Endocrinology.

LH-RH analogue carrying a cytotoxic radical is internalized by rat pituitary cells in vitro

A. Schally, K. Groot, Z. Rékási, 1994, Peptides.

Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs

E. Rodríguez-Martín, A. Schally, K. Groot, 1999, Journal of Cancer Research and Clinical Oncology.

Effect of long-term treatment with low doses of the LHRH antagonist Cetrorelix on pituitary receptors for LHRH and gonadal axis in male and female rats.

A. Bajo, A. Schally, K. Groot, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Effects of long-term treatment with the luteinizing hormone-releasing hormone (LHRH) agonist Decapeptyl and the LHRH antagonist Cetrorelix on the levels of pituitary LHRH receptors and their mRNA expression in rats

A. Bajo, A. Schally, K. Groot, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers

B. Szende, A. Schally, F. Hébert, 2000, British Journal of Cancer.

Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours.

A. Schally, F. Hébert, K. Groot, 2000, European journal of cancer.

Luteinizing hormone‐releasing hormone antagonist Cetrorelix (SB‐75) and bombesin antagonist RC‐3940‐II inhibit the growth of androgen‐independent PC‐3 prostate cancer in nude mice

A. Schally, K. Groot, K. Szepesházi, 1997, The Prostate.

Inhibition of PC‐3 human prostate cancers by analogs of growth hormone‐releasing hormone (GH‐RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity

A. Schally, M. Krupa, K. Groot, 2002, International journal of cancer.

Bombesin antagonists inhibit estrogen-independent breast the expression of the ErbB-2, and c-jun and c-fos oncogenE

A. Bajo, A. Schally, M. Krupa, 2016 .

Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.

A. Schally, K. Groot, K. Szepesházi, 1994, Acta oncologica.

Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.

A. Schally, K. Groot, K. Szepesházi, 1998, European journal of cancer.

Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.

A. Schally, K. Groot, Gabor L. Toller, 2005, The Journal of clinical endocrinology and metabolism.

Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207.

C. Logothetis, A. Schally, M. Krupa, 2002, Cancer letters.

in vivo inhibition of PC‐3 human androgen‐independent prostate cancer by a targeted cytotoxic bombesin analogue, AN‐215

A. Schally, K. Groot, Baodong Sun, 2000, International journal of cancer.

Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.

A. Schally, F. Hébert, K. Groot, 2003, Cancer research.

Carcinoma the Proliferation of Experimental Non-Small Cell Lung Antagonists of Growth Hormone-Releasing Hormone Inhibit

A. Schally, F. Hébert, K. Groot, 2003 .

Complete regression of MX‐1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone–releasing hormone, AN‐207

A. Schally, K. Groot, J. M. Arencibia, 1999, Cancer.

Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice

A. Schally, K. Groot, J. M. Arencibia, 2000, Breast Cancer Research and Treatment.

Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.

A. Schally, K. Groot, K. Szepesházi, 1997, Journal of the National Cancer Institute.

Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone.

A. Schally, K. Groot, A. Jungwirth, 1997, British Journal of Cancer.

Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.

A. Schally, K. Groot, K. Szepesházi, 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.

A. Schally, K. Groot, G. Halmos, 1996, Endocrinology.

Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.

A. Schally, K. Groot, Z. Rékási, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitory effect of bombesin/gastrin‐releasing peptide antagonist RC‐3095 and luteinizing hormone—releasing hormone antagonist SB‐75 on the growth of MCF‐7 MIII human breast cancer xenografts in athymic nude mice

A. Schally, K. Groot, K. Szepesházi, 1994, Cancer.

Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.

A. Schally, K. Groot, K. Szepesházi, 1994, British Journal of Cancer.

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

A. Schally, K. Groot, K. Szepesházi, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Somatostatin receptor expression in lung cancer.

K. O'Byrne, A. Schally, K. Groot, 1994, European journal of cancer.

Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma.

A. Schally, K. Groot, A. Jungwirth, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly.

R. Kineman, A. Schally, K. Groot, 1997, Endocrinology.

Inhibitory effects of antagonistic analogs of GHRH on GH3 pituitary cells overexpressing the human GHRH receptor.

Eun-Jig Lee, A. Schally, K. Groot, 2002, The Journal of endocrinology.

Inhibition of GH Release in Rats by New Potent Antagonists of Growth Hormone-Releasing Hormone (GH-RH)

A. Schally, K. Groot, M. Zarándi, 1997, Peptides.

Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.

A. Schally, K. Groot, G. Halmos, 1996, Endocrinology.

Development of a radioimmunoassay for some agonists of growth hormone-releasing hormone.

A. Schally, K. Groot, V. Csernus, 2009, International journal of peptide and protein research.

Chronic administration of a new potent agonist of growth hormone- releasing hormone induces compensatory linear growth in growth hormone-deficient rats: mechanism of action.

A. Schally, K. Groot, G. Halmos, 1996, Neuroendocrinology.

Synthesis and In Vitro Evaluation of New Potent Antagonists of Growth Hormone-Releasing Hormone (GH-RH)

A. Schally, K. Groot, Z. Kele, 1997, Peptides.

Pancreatic immunoreactive somatostatin and diabetes mellitus

K. Groot, A. Arimura, J. Ryan, 1984, Digestive Diseases and Sciences.

Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth.

A. Schally, F. Hébert, K. Groot, 2001, Endocrinology.

New analogs of human growth hormone-releasing hormone (1-29) with high and prolonged antagonistic activity.

A. Schally, K. Groot, A. Nagy, 2009, The journal of peptide research : official journal of the American Peptide Society.

Comparison of GH-stimulation by GH-RH(1-29)NH2 and an agmatine29 GH-RH analog, after intravenous, subcutaneous and intranasal administration and after pulmonary inhalation in rats.

A. Schally, K. Groot, T. Yano, 2009, International journal of peptide and protein research.

A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers.

A. Schally, K. Groot, K. Szepesházi, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Somatostatin analog RC‐160 inhibits the growth of human osteosarcomas in nude mice

A. Schally, K. Groot, K. Szepesházi, 1996, International journal of cancer.

Increased activity of antagonists of growth hormone-releasing hormone substituted at positions 8, 9, and 10.

A. Schally, K. Groot, Gabor L. Toller, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities.

A. Schally, K. Groot, V. Csernus, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogendependent MXT mouse mammary cancers: Correlations between growth characteristics and EGF receptor content of tumors

A. Schally, K. Groot, K. Szepesházi, 2005, Breast Cancer Research and Treatment.

Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes.

A. Schally, K. Groot, V. Csernus, 1989, Endocrinology.

Effects of high-fat diet on the patterns of prostatic cancer induced in rats by N-nitrosobis(2-oxopropyl)amine and testosterone.

P. Pour, A. Schally, K. Groot, 1991, Cancer research.

Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.

A. Schally, K. Groot, Z. Rékási, 2000, Endocrinology.

Effect of chronic administration of a new potent agonist of GH-RH(1–29)NH2 on linear growth and GH responsiveness in rats

A. Schally, K. Groot, A. Jungwirth, 1996, Regulatory Peptides.

Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors.

A. Schally, K. Groot, M. Koppán, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Targeted cytotoxic analog of luteinizing hormone‐releasing hormone AN‐207 inhibits the growth of PC‐82 human prostate cancer in nude mice

A. Schally, K. Groot, M. Koppán, 1999 .

Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines.

A. Schally, K. Groot, T. Yano, 1992, Cancer research.

Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II.

A. Schally, K. Groot, K. Szepesházi, 1997, European journal of cancer.

Antagonists of bombesin/gastrin‐releasing peptide inhibit growth of SW‐1990 human pancreatic adenocarcinoma and production of cyclic AMP

A. Schally, K. Groot, T. Ertl, 1995, International journal of cancer.

Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.

A. Schally, K. Groot, K. Szepesházi, 1992, Journal of the National Cancer Institute.

Inhibition of growth of PC‐82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC‐3095 or combination of agonist [D‐Trp6]‐luteinizing hormone‐releasing hormone and somatostatin analog RC‐160

A. Schally, K. Groot, S. Radulović, 1992, The Prostate.

Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.

A. Schally, K. Groot, K. Szepesházi, 1994, Cancer research.

Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi.

A. Schally, K. Groot, S. Radulović, 2009, International journal of peptide and protein research.

Inhibition of the growth of caki‐I human renal adenocarcinoma in Vivo by luteinizing hormone‐releasing hormone antagonist cetrorelix, somatostatin analog RC‐160, and bombesin antagonist RC‐3940‐II

A. Schally, K. Groot, K. Szepesházi, 1998, Cancer.

Effect of bombesin, gastrin‐releasing peptide (GRP)(14–27) and bombesin/GRP receptor antagonist RC‐3095 on growth of nitrosamine‐induced pancreatic cancers in hamsters

A. Schally, K. Groot, K. Szepesházi, 1993, International journal of cancer.

Antiserum to rat growth hormone (GH)-releasing factor suppresses but does not abolish antisomatostatin-induced GH release in the rat.

K. Groot, A. Arimura, C. Thomas, 1985, Endocrinology.

Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide

A. Schally, K. Groot, H. Kiaris, 1999, Oncogene.

Receptors for d-Trp6-Luteinizing Hormone-Releasing Hormone, Somatostatin, and Insulin-Like Growth Factor I in MXT Mouse Mammary Carcinoma

B. Szende, A. Schally, K. Groot, 1989, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Somatostatin in human pancreatic and gastric juice

A. Vinik, K. Groot, A. Arimura, 1981, Peptides.

The Expression of Growth Hormone-Releasing Hormone (GHRH) and its Receptor Splice Variants in Human Breast Cancer Lines; The Evaluation of Signaling Mechanisms in the Stimulation of Cell Proliferation

A. Schally, K. Groot, J. Varga, 2004, Breast Cancer Research and Treatment.

Inhibition of growth of MDA‐MB‐468 estrogen‐independent human breast carcinoma by bombesin/gastrin‐releasing peptide antagonists RC‐3095 and RC‐3940‐II

A. Schally, K. Groot, J. M. Arencibia, 2000, Cancer.

Inhibition of proliferation of PC‐3 human prostate cancer by antagonists of growth hormone–releasing hormone: Lack of correlation with the levels of serum IGF‐I and expression of tumoral IGF‐II and vascular endothelial growth factor

A. Schally, M. Krupa, F. Hébert, 2002, The Prostate.

Effect of GHRH and peptides from the vasoactive intestinal peptide family on cAMP production of human cancer cell lines in vitro.

A. Schally, K. Groot, V. Csernus, 1999, The Journal of endocrinology.

Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro☆

A. Schally, K. Groot, V. Csernus, 1999, Peptides.

Inhibitory effects of analogs of luteinizing hormone‐releasing hormone and somatostatin on pancreatic cancers in hamsters events that accompany tumor regression

B. Szende, A. Schally, K. Groot, 1990, Cancer.

Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix.

A. Schally, K. Groot, M. Vadillo-Buenfil, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats.

A. Schally, K. Groot, A. Jungwirth, 1996, Endocrinology.

Investigational strategies for detection and intervention in early-stage pancreatic cancer

I. Zagon, S. Hubchak, M. Korc, 1994, International journal of pancreatology : official journal of the International Association of Pancreatology.

Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75.

A. Schally, K. Groot, S. Bajusz, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers.

R. Kineman, A. Schally, K. Groot, 1999, The Journal of clinical endocrinology and metabolism.

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC‐3 and DU‐145 human androgen‐independent prostate cancers

A. Schally, K. Groot, G. Halmos, 2005, The Prostate.

The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues.

K. Kovitz, A. Schally, K. Groot, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.

A. Schally, K. Groot, Gabor L. Toller, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors

A. Schally, M. Krupa, K. Groot, 2002, Regulatory Peptides.

The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas

A. Schally, K. Groot, K. Szepesházi, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone

A. Schally, K. Groot, G. Halmos, 2001, Anti-cancer drugs.

Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways

A. Schally, K. Groot, Z. Rékási, 2001, Peptides.

Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.

A. Schally, K. Groot, G. Halmos, 2001, The Journal of clinical endocrinology and metabolism.

Growth hormone-releasing hormone: an autocrine growth factor for small cell lung carcinoma.

A. Schally, K. Groot, H. Kiaris, 1999, Proceedings of the National Academy of Sciences of the United States of America.

GRHきっ坑薬のMZ‐5‐156は,ヌードマウスのDU‐145ヒトアンドロゲン非依存性前立腺癌の成長を阻害し,腫よう内のIGF2のレベル及びmRNA発現を低下させる

A. Schally, K. Groot, M. Koppán, 1998 .

Inhibition of growth of human small cell and non-small cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH).

A. Schally, K. Groot, A. Jungwirth, 1996, International journal of oncology.

Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone.

A. Schally, K. Groot, K. Szepesházi, 1995, Journal of the National Cancer Institute.

In vivo and in vitro release of ACTH by synthetic CRF

C. Turkelson, K. Groot, M. Culler, 1981, Peptides.

Combination treatment of nitrosamiee-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist

A. Schally, K. Groot, K. Szepesházi, 1994, International journal of pancreatology : official journal of the International Association of Pancreatology.

Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers

A. Bajo, A. Schally, K. Groot, 2004, British Journal of Cancer.

Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists.

B. Szende, A. Schally, K. Groot, 1990, Cancer research.

Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH

R. Clarke, A. Schally, K. Groot, 1992, Breast Cancer Research and Treatment.

Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.

B. Szende, A. Schally, K. Groot, 1990, Journal of the National Cancer Institute.

Development of radioimmunoassay for a potent luteinizing hormone-releasing hormone antagonist. Evaluation of serum levels after injection of [Ac-3-(2-naphthyl)-D-Ala1, D-Phe(pCl)2, 3-(3-pyridyl)-D-Ala3, D-Cit6, D-Ala10] LHRH.

B. Szende, A. Schally, K. Groot, 1990, Arzneimittel-Forschung.

Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination

A. Schally, K. Groot, K. Szepesházi, 1992, Breast Cancer Research and Treatment.

Antitumor effects of analogs of LH-RH and somatostatin: Experimental and clinical studies

B. Szende, A. Schally, K. Groot, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Isolation and characterization of two peptides with prolactin release-inhibiting activity from porcine hypothalami.

A. Schally, K. Groot, J. Stults, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of growth of MX‐1, MCF‐7‐MIII and MDA‐MB‐231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN‐238

A. Schally, K. Groot, Baodong Sun, 1999, International journal of cancer.

Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75).

A. Schally, K. Groot, K. Szepesházi, 1993, Journal of andrology.

Luminal gastric somatostatin-like immunoreactivity in response to various stimuli in man

K. Groot, A. Arimura, A. Ertan, 1986, Digestive Diseases and Sciences.

Evaluation of the in vitro and in vivo activity of the L-, D,L- and D-Cit6 forms of the LH-RH antagonist Cetrorelix (SB-75).

A. Schally, K. Groot, G. Srkalović, 2009, International journal of peptide and protein research.

Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.

A. Schally, K. Groot, A V Schally, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of growth of experimental prostate cancer in rats by LH‐RH analogs linked to cytotoxic radicals

A. Schally, K. Groot, K. Szepesházi, 1993, The Prostate.

Recovery of pituitary function after treatment with a targeted cytotoxic analog of luteinizing hormone-releasing hormone.

A. Schally, K. Groot, M. Koppán, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Evaluation of biological activities of new LH-RH antagonists (T-series) in male and female rats.

A. Schally, K. Groot, T. Yano, 2009, International journal of peptide and protein research.

Comparison of biological effects of a sustained delivery system and nonencapsulated LH-RH antagonist SB-75 in rats

A. Schally, K. Groot, T. Yano, 1992, Peptides.

Synthesis and biological evaluation of superactive agonists of growth hormone-releasing hormone.

A. Schally, K. Groot, J. Horváth, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin.

W. Banks, A. Kastin, A. Schally, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.

A. Schally, K. Groot, M. Koppán, 1999, The Prostate.

Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.

K. Groot, K. Szepesházi, J. M. Arencibia, 2001, Cancer letters.

Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.

A. Schally, K. Groot, Z. Rékási, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.

A. Schally, K. Groot, H. Reile, 1994, Cancer research.

Inhibitory effects of analogs of luteinizing hormone‐releasing hormone on the growth of the androgen‐independent dunning R‐3327‐AT‐1 rat prostate cancer

A. Schally, K. Groot, G. Halmos, 1994, International journal of cancer.

Effect of microcapsules of luteinizing hormone‐releasing hormone antagonist SB‐75 and somatostatin analog RC‐160 on endocrine status and tumor growth in the dunning R‐3327H rat prostate cancer model

A. Schally, K. Groot, K. Szepesházi, 1992, The Prostate.

Potentiation of the inhibitory effect of growth hormone‐releasing hormone antagonists on PC‐3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

A. Schally, K. Groot, Z. Rékási, 2000, The Prostate.

Somatostatin analog RC‐160 inhibits growth of CFPAC‐1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate

A. Schally, K. Groot, T. Ertl, 1995, International journal of cancer.

Antitumor effects of analogs of somatostatin and antagonists of bombesin/GRP in experimental models of pancreatic cancer

A. Schally, K. Groot, K. Szepesházi, 1994 .

Effect of long-acting antagonists of growth hormone (GH)-releasing hormone on GH and cyclic adenosine 3',5'-monophosphate release in superfused rat pituitary cells.

A. Schally, K. Groot, J. Horváth, 1995, Endocrinology.

Growth hormone-releasing hormone stimulates cAMP release in superfused rat pituitary cells.

A. Schally, K. Groot, J. Horváth, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent.

M Kovacs, A. Schally, K. Groot, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.

A. Schally, K. Groot, Gabor L. Toller, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Radioimmunoassay for octapeptide analogs of somatostatin: measurement of serum levels after administration of long-acting microcapsule formulations.

A. Schally, K. Groot, J. Horváth, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and in vitro and in vivo activity of analogs of growth hormone-releasing hormone (GH-RH) with C-terminal agmatine.

A. Schally, K. Groot, V. Csernus, 2009, International journal of peptide and protein research.

Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.

A. Schally, K. Groot, K. Szepesházi, 1997, Anti-cancer drugs.

Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin.

A. Schally, K. Groot, K. Szepesházi, 1997, International journal of oncology.

Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK‐ES‐1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone‐releasing hormone

A. Schally, M. Krupa, K. Groot, 2002, Cancer.

Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide

A. Bajo, A. Schally, K. Groot, 2001, Journal of Cancer Research and Clinical Oncology.

Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers.

A. Schally, K. Groot, J. Varga, 2004, European journal of cancer.

Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215

A. Bajo, A. Schally, K. Groot, 2002, British Journal of Cancer.

Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities.

A. Schally, K. Groot, Gabor L. Toller, 2006, Proceedings of the National Academy of Sciences of the United States of America.

The Prostate 68 : 1763 ^ 1772 ( 2008 ) Dose-DependentGrowth Inhibition InVivoof PC-3 ProstateCancerWith aReduction in TumoralGrowth FactorsAfterTherapyWith GHRHAntagonistMZ-J-7-138

A. Schally, K. Groot, G. Halmos, 2008 .

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers

A. Schally, K. Groot, G. Halmos, 2005 .

The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA‐PCa‐2b and LuCaP‐35 prostate cancers

A. Schally, K. Groot, A. Havt, 2007, The Prostate.

Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.

A. Schally, K. Groot, K. Szepesházi, 2003, Cancer research.

Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

A. Schally, K. Groot, K. Szepesházi, 1994, Proceedings of the National Academy of Sciences of the United States of America.

Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats.

A. Schally, K. Groot, S. Radulović, 1992, The American journal of physiology.

In vitro pituitary hormone releasing activity of 40 residue human pancreatic tumor growth hormone releasing factor

C. Turkelson, K. Groot, M. Culler, 1983, Peptides.

Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin

A. Schally, K. Groot, J. Varga, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Suppression of testicular activity by a GnRH agonist in hypophysectomized, gonadotropin-treated mice.

K. Groot, A. Arimura, K. Iwasaki, 1989, The Tokai journal of experimental and clinical medicine.

Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.

A. Schally, K. Groot, H. Reile, 1994, Cancer research.

Somatostatin receptor expression in lung cancer.

K. Groot, K. Szepesházi, D. Carney, 1994, European journal of cancer.

Development of a radioimmunoassay for a pseudononapeptide bombesin/GRP antagonist with antitumor activity.

A. Schally, K. Groot, J. Horváth, 2009, International journal of peptide and protein research.